Estrogen Receptor-Alpha, Breast Cancer Patients And Tamoxifen Response

Researchers have found evidence of a statistically significant survival benefit from adjuvant tamoxifen among patients whose estrogen receptor (ER)-positive tumors had high levels of phosphorylation of ER-alpha; at serine-118 (ER-alpha S118-P), according to a brief communication published online November 25 in the Journal of the National Cancer Institute. Approximately 50% of breast carcinomas are resistant to tamoxifen.

source : www.medicalnewstoday.com

Related News:

• Gaps Remain in Cancer Palliative Care
• Testicular Cancer Treatments Worse than the Disease
• Charlotte Gerson talks out about the cancer industry and natural cancer remedies
• Discovery Of Opposing Functions Of A Key Molecule In The Development Of Organisms Could Benefit Cancer Research
• SGO: Drug Combination Slows Recurrent Ovarian Cancer
• Researchers Develop Tool To Help Study Prostate Cancer
• Home Specimen Collection Boosts Cervical Cancer Screening
• Vitamin D slashes risk of bowel cancer by 40 percent
• Reovirus may be a novel approach to prostate cancer treatment
• MHNCS: PET May Predict Cancer Aggression (CME/CE)